MTVA · MetaVia Inc.
$1.54
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due in large part to the ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.94M
Shares
6.59M
Volume · Oct 5
52.67K
Avg daily vol (3M)
234.63K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.54
Open$1.56
Day$1.51–1.65
52W close$0.97–11.99
Avg vol 30d82K
Short int183K · 2.8% float · 1.5d
Short vol20%
Last earningsJan 1, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$14.45M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$12.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+326.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.8%
Latest settlement · 1.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−36%
below
Price vs 50-day avg
−2%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
5%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−16%
trailing
6-month return
+3%
trailing
YTD return
−82%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+42% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.78% of float · ▼ -13.0% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
17 holders — near 6-yr high, broad support
Squeeze score
39
low risk · 0–100
Fundamentals
EPS growth
+81%
Y/Y
Free cash flow
$-15.7M
Quant / Vol
risk profile
Volatility
150%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−36%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+42% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.78% of float · ▼ -13.0% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
17 holders — near 6-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 5%
Range high $12
vs 200-day avg -36%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTVA
this stock
MetaVia Inc.
|
$10.94M | -81.7% | — | — | 2.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTVA | -7.2% | -16.3% | +2.7% | -1.9% | -81.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.0% | -15.8% | -9.5% | -2.8% | -94.6% |